title: Inolimomab (OPi).
abstract: OPi (formerly Orphan Pharma International) is developing inolimomab, an anti-interleukin-2 receptor (CD25) monoclonal antibody for the potential treatment of acute graft versus host disease. As of April 2001, inolimomab was undergoing phase II/III clinical trials.
authors.affiliation: Klinik für Visceral- und Transplantationschirurgie, Transplantationschirurgie, Medizinische Hochschule Hannover, Germany. Winkler.Michael@mh-Hannover.de
authors.forename: Michael
authors.initials: M
authors.lastname: Winkler
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D006086:Graft vs Host Disease / Q000188:drug therapy*; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; C079843:inolimomab